BioLife Solutions, Inc.
BLFSHealthcareNASDAQMedical Instruments & Supplies · Last scanned Jul 18, 2026
Scan Results
Daily timeframePart of the healthcare sector, BioLife Solutions, Inc. (BLFS) is listed under Medical Instruments & Supplies. The $1.42B market capitalization puts BLFS squarely in small-cap range for its industry. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
Market Cap
$1.42B
Beta
1.94
P/E (TTM)
—
P/E (Fwd)
88.33
EPS (TTM)
$-0.23
EPS (Fwd)
$0.33
ROE
-3.1%
ROA
-0.1%
Cash
$81.0M
Total Debt
$14.9M
Free CF
$6.4M
52W Change
39.9%
Annual Financials
Cash vs Debt
With $81.0M in cash and $14.9M in debt, BLFS maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Annual free cash flow of $6.4M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -3.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $76.2M (2022) to $96.2M (2025), reflecting a 26% increase over the period.
BioLife Solutions, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, BLFS has financial flexibility that may help navigate uncertain periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence BioLife Solutions, Inc.'s trajectory.